Measurement of interleukin-1 receptor antagonist in patients with systemic lupus erythematosus could predict renal manifestation of the disease

Boglarka Brugos, Emese Kiss, Csaba Dul, Wolfgang Gubisch, Gyula Szegedi, Sandor Sipka, Margit Zeher

Research output: Contribution to journalArticle

13 Citations (Scopus)


Interleukin-1 receptor antagonist (IL-1Ra) is a good indicator of disease activity in patients with systemic lupus erythematosus (SLE). Glucocorticosteroids are the most frequently used drugs in SLE. Our goal was to compare IL-1Ra activity in SLE patients with and without renal involvement and to determine the effect of different dosage of glucocorticosteroids used in 17 patients with active SLE without nephritis, 7 patients with inactive lupus nephritis (LN), and 8 patients with active LN, along with 10 healthy controls. IL-1Ra levels were measured in the serum of SLE patients by Human Luminex [100] analyzer. Both in patients with active SLE without nephritis and in patients with LN, serum levels of IL-1Ra (p<0.001) were significantly higher compared with those in the controls. IL-1Ra was significantly higher in patients with active LN than in patients with inactive LN (p = 0.028). The use of methylprednisolone was significantly higher in the active LN group compared with the inactive LN group (p = 0.013). SLE patients with higher IL-1Ra are at lower risk for developing nephritis. The higher doses of glucocorticosteroids needed in active LN could be due to steroid resistance and IL-1Ra polymorphism. Measurement of IL-1Ra levels in SLE patients could help to predict future renal involvement.

Original languageEnglish
Pages (from-to)874-877
Number of pages4
JournalHuman Immunology
Issue number9
Publication statusPublished - Sep 1 2010



  • Active SLE
  • Creatinine clearance
  • Interleukin-1 receptor antagonist
  • Lupus nephritis
  • Methylprednisolone

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this